Cellarity
PrivateLast Round
Series C
Oct 4, 2022
Est. Valuation
$621M
Total Funding Raised
$274M
Company Overview
Cellarity operates in Healthcare & Life Sciences and is based in Somerville, Massachusetts. Its latest recorded funding round was a Series C round in October 2022.
Cellarity is a biotechnology company that develops oral therapeutics by utilizing an artificial intelligence platform to study and correct whole cell-state dysfunction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cellarity Comparables
Compare Cellarity with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valo Health | 84% | |
| Iambic Therapeutics | 82% | |
| Insitro | 81% |
For institutional investors. Book with your work email.
Cellarity Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 4, 2022 | ||||
| Series B | Feb 25, 2021 | ||||
| Series A | Dec 10, 2019 |
For institutional investors. Book with your work email.
Cellarity Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pictet Group | Series B |
| JIMCO | Series B |
| Flagship Pioneering | Series C, Series B, Series A |
| BlackRock | Series B |
| Hanwha Impact | Series C |
| The Baupost Group | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 4, 2025
Two oral presentations at the 67th ASH Annual Meeting.
- May 12, 2025
Ted Myles appointed as the new Chief Executive Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- merges_withOct 29, 2026
Flagship Pioneering merges Cellarity, Inc., Etiome and Empress Therapeutics into Etcelera, a single drug discovery business, in Massachusetts on Oct 29th '26.
- merges_withOct 29, 2026
Cellarity, Inc. and Empresstx combine with Etiome under Flagship Pioneering to form Etcelera, an artificial intelligence-focused drug development company that launches in Massachusetts on Oct 29th '26.
For institutional investors. Book with your work email.
Cellarity Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cellarity's valuation, stock price, and market status.
Is Cellarity a public or private company?
Cellarity is a private company.
What is the current stock price of Cellarity?
Cellarity is a private company, so its shares have no public market price. Caplight tracks Cellarity's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cellarity worth (valuation)?
Cellarity's valuation is estimated at $621.0M based on funding round data.
Can I buy Cellarity stock?
Cellarity shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cellarity's last funding round?
Cellarity's most recent funding round was Series C on October 4, 2022.
Who are the main investors in Cellarity?
Key investors in Cellarity include Pictet Group, Flagship Pioneering, BlackRock, The Baupost Group.
Will Cellarity IPO soon?
No public IPO plans have been announced for Cellarity.
How can I track Cellarity secondary market activity?
Caplight tracks bids, offers, and trades in Cellarity's shares on secondary markets.